

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Currently Amended) ~~Use of silibinin, its salts and/or its pro-drugs with α -lipoic acid, its salts and/or its pro-drugs for the production of a medicine for the simultaneous, separate or timed~~ A method for the cytoprotective treatment of chronically obstructive lung, comprising administering to a subject in need thereof an effective dose of

(a) sibilin or a salt thereof

and

(b) α -lipoic acid or a salt thereof,

wherein each of (a) and (b) are administered to said subject by inhalation in a simultaneous, separate, or timed manner ~~diseases.~~

Claim 2. (Currently Amended) ~~Use~~ The method according to claim 1, ~~characterised in that the dose of the α -lipoic acid, its salts and/or its pro-drugs for administration to~~ wherein said subject is a human patient and the dose of said α -lipoic acid or a salt thereof is between 30 and 1800 mg/d, ~~preferably between 200 and 600 mg/d.~~

Claim 3. (Currently Amended) ~~Use~~ The method according to Claim 1, ~~characterised in that the dose of silibinin, its salts and/or its pro-drugs for administration to~~ wherein said subject is a human patient and the dose of said sibilin or a salt thereof is between 20 and 1600 mg/d, ~~preferably between 300 and 800 mg/d.~~

Claim 4. (Cancelled)

Claim 5. (Currently Amended) ~~Use~~ The method according to Claim 1, comprising administering to said subject an additive which is an aqueous solvent, a stabilizer, a suspending agent, a dispersing agent or a wetting agent ~~characterised in that the medicine contains further additives selected from the group of aqueous solvents, stabilisers, suspending, dispersing and wetting agents.~~

Claim 6. (Currently Amended) Use The method according to Claim 1, ~~characterised in that the medicine wherein each of (a) and (b) is presented in the form of an aerosol, a solution, granules, a powder, an emulsion, a tablet and/or a film tablet.~~

Claim 7. (Currently Amended) Use The method according to Claim 1, ~~characterised in that silibinin, its salts and/or its pro-drugs or a salt thereof and the α -lipoic acid, its salts and/or its pro-drugs are or a salt thereof is presented in a single formulation.~~

Claim 8. (Currently Amended) Use The method according to Claim 1, ~~characterised in that silibinin, its salts and/or its pro-drugs or a salt thereof and the α -lipoic acid, its salts and/or its pro-drugs or a salt thereof are presented in separate formulations.~~

Claim 9. (Cancelled)

Claim 10. (Currently Amended) Use The method according to Claim 1, ~~characterised in that the wherein an effector of glutathione metabolism and the α -lipoic acid, its salts and/or its pro-drugs or a salt thereof are presented in a single formulation.~~

Claim 11. (Currently Amended) Use The method according to Claim 1, ~~characterised in that the wherein an effector of glutathione metabolism and the α -lipoic acid, its salts and/or its pro-drugs or a salt thereof are presented in separate formulations.~~

Claim 12. (Currently Amended) Use The method according to claim 1 comprising administering to said subject silibinin and α -lipoic acid. for the simultaneous, separate or timed cytoprotective treatment of chronically obstructive lung diseases comprising administering silibinin, its salts and/or its pro-drugs with α -lipoic acid

Claim 13. (New) The method according to claim 2, wherein the dose of α -lipoic acid or a salt thereof is between 200 and 600 mg/d.

Claim 14. (New) The method according to claim 3, wherein the dose of sibilin or a salt thereof is between 300 and 800 mg/d.

Claim 15. (New)

The method according to Claim 1, wherein said subject is a human patient and the dose of said sibilin or a salt thereof is between 20 and 1600 mg/d and the dose of said α -lipoic acid or a salt thereof is between 30 and 1800 mg/d.